Video

Dr. Berg highlights key ongoing trials in urothelial cancer

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Stephanie Berg, DO, highlights key ongoing trials in advanced/metastatic urothelial cancer, including EV-302 (NCT04223856), NILE (NCT03682068) CheckMate-901 (NCT03036098), and MAIN-CAV (NCT05092958).Berg is an instructor of medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute.

      Related Videos
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
      Urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Expert describes implications of neoadjuvant durvalumab approval in MIBC
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      How rBCG EAP could open up access for Anktiva in bladder cancer
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
      Related Content
      Human Body Organs (Urinary Bladder) | Image Credit: @ magicmine - stock.adobe.com
      April 21st 2025

      Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

      Hannah Clarke
      Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      April 17th 2025

      NMIBC Clinical Forums highlight novel therapies and treatment strategies

      Urology Times staff
      Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      FDA approval sought for Anktiva in papillary NMIBC
      April 15th 2025

      FDA approval sought for Anktiva in papillary NMIBC

      Hannah Clarke
      The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
      What urologists can expect in Q2 of 2025
      April 7th 2025

      What urologists can expect in Q2 of 2025

      Hannah Clarke Benjamin P. Saylor
      A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
      © 2025 MJH Life Sciences

      All rights reserved.